Biomarker Testing in Non-Small Cell Lung Cancer A Clinician's Perspective

[11] Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : 823 - 859

[12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139

[13] Detection of mutations in EGFR in circulating lung-cancer cells [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 366 - 377

[14] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957

[15] Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer [J]. CANCER SCIENCE, 2013, 104 (10) : 1346 - 1352

[16] Ou SI., 2013, J Clin Oncol, V31, pabstract 8032, DOI [DOI 10.1200/JCO.2013.31.15SUPPL.8032, 10.1200/jco.2013.31.15suppl.8032]

[17] Powderly JD, 2013, J CLIN ONCOL, V31

[18] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246

[19] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) : 92 - 98

[20] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3327 - +

[11] Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : 823 - 859

[12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139

[13] Detection of mutations in EGFR in circulating lung-cancer cells [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 366 - 377

[14] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957

[15] Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer [J]. CANCER SCIENCE, 2013, 104 (10) : 1346 - 1352

[16] Ou SI., 2013, J Clin Oncol, V31, pabstract 8032, DOI [DOI 10.1200/JCO.2013.31.15SUPPL.8032, 10.1200/jco.2013.31.15suppl.8032]

[17] Powderly JD, 2013, J CLIN ONCOL, V31

[18] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J]. LANCET ONCOLOGY, 2012, 13 (03) : 239 - 246

[19] Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) : 92 - 98

[20] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3327 - +